Chargement en cours...
Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies
Individual patients with life-threatening or severely debilitating diseases can petition the U.S. Food and Drug Administration (FDA) through their physicians to have expanded access (EA) to drugs that are in clinical trials but have not reached full FDA approval (the “single-patient” investigational...
Enregistré dans:
| Publié dans: | JACC Basic Transl Sci |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6058931/ https://ncbi.nlm.nih.gov/pubmed/30062226 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacbts.2018.02.001 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|